The Food and Drug Administration has issued draft guidance aimed at making it easier to develop personalized gene-editing treatments for patients with rare genetic diseases, including conditions in which each patient may carry a different mutation.

The proposal would create a framework for multiple patient-specific versions of a treatment to be covered by one biologics license application, rather than treating every variation as an entirely separate product.

A shared framework for tailored treatments

The draft centers on an “individualized feature space,” a set of defined limits on how a treatment can vary while keeping the same core design. A new patient-specific version that falls within those limits could be added after approval using laboratory evidence of safety and activity, without necessarily requiring a new clinical trial for each version.

That approach would build on the clinical evidence supporting the original approval. It would not remove the need for safety testing or mean that all gene-editing products could skip clinical trials.

According to independent coverage by FDA Webview, changes outside the approved limits could require additional review and clinical evidence. A change that fundamentally alters the editing mechanism or introduces significant new risks would require a separate application.

Safety and public comment

The guidance also addresses manufacturing, product quality, naming and labeling, and testing for unintended genetic changes. Developers would have to explain how the evidence supports the range of patient-specific versions they want included.

The document is a draft, not approval of a new therapy or evidence that a particular treatment is a cure. The FDA is seeking public comment before finalizing its approach.

Separate plans to broaden access

The Centers for Medicare & Medicaid Services also announced plans to broaden its Cell and Gene Therapy Access Model beyond sickle cell disease. The voluntary model uses outcomes-based agreements negotiated with manufacturers on behalf of state Medicaid programs.

CMS says it will invite applications from manufacturers for therapies targeting other conditions in the coming months. That is a planned expansion, not confirmation that every new gene therapy is already covered or available to patients.

Details are available in the Department of Health and Human Services announcement.